588 related articles for article (PubMed ID: 20347337)
1. Implantable cardioverter-defibrillator shocks in patients with a left ventricular assist device.
Ambardekar AV; Allen LA; Lindenfeld J; Lowery CM; Cannon AP; Cleveland JC; Brieke A; Sauer WH
J Heart Lung Transplant; 2010 Jul; 29(7):771-6. PubMed ID: 20347337
[TBL] [Abstract][Full Text] [Related]
2. Persistent atrial fibrillation is associated with appropriate shocks and heart failure in patients with left ventricular dysfunction treated with an implantable cardioverter defibrillator.
Rienstra M; Smit MD; Nieuwland W; Tan ES; Wiesfeld AC; Anthonio RL; Van den Berg MP; Van Veldhuisen DJ; Van Gelder IC
Am Heart J; 2007 Jan; 153(1):120-6. PubMed ID: 17174649
[TBL] [Abstract][Full Text] [Related]
3. The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices.
Enriquez AD; Calenda B; Miller MA; Anyanwu AC; Pinney SP
Circ Arrhythm Electrophysiol; 2013 Aug; 6(4):668-74. PubMed ID: 23873139
[TBL] [Abstract][Full Text] [Related]
4. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.
Chan PS; Nallamothu BK; Spertus JA; Masoudi FA; Bartone C; Kereiakes DJ; Chow T
Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):16-24. PubMed ID: 20031808
[TBL] [Abstract][Full Text] [Related]
5. Left ventricular mechanical assist devices and cardiac device interactions: an observational case series.
Foo D; Walker BD; Kuchar DL; Thorburn CW; Tay A; Hayward CS; Macdonald P; Keogh A; Kotlyar E; Spratt P; Jansz P
Pacing Clin Electrophysiol; 2009 Jul; 32(7):879-87. PubMed ID: 19572863
[TBL] [Abstract][Full Text] [Related]
6. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous use of implantable cardioverter-defibrillators and left ventricular assist devices in patients with severe heart failure.
Kühne M; Sakumura M; Reich SS; Sarrazin JF; Wells D; Chalfoun N; Crawford T; Boonyapisit W; Horwood L; Chugh A; Good E; Jongnarangsin K; Bogun F; Oral H; Morady F; Pagani F; Pelosi F
Am J Cardiol; 2010 Feb; 105(3):378-82. PubMed ID: 20102952
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of implantable cardioverter-defibrillators in patients with ischemic heart disease and left ventricular dysfunction.
Chan PS; Chow T; Kereiakes D; Schloss EJ; Waller T; Eagle K; Hayward RA; Vijan S
Arch Intern Med; 2006 Nov; 166(20):2228-33. PubMed ID: 17101941
[TBL] [Abstract][Full Text] [Related]
9. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
[TBL] [Abstract][Full Text] [Related]
10. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator.
Roes SD; Borleffs CJ; van der Geest RJ; Westenberg JJ; Marsan NA; Kaandorp TA; Reiber JH; Zeppenfeld K; Lamb HJ; de Roos A; Schalij MJ; Bax JJ
Circ Cardiovasc Imaging; 2009 May; 2(3):183-90. PubMed ID: 19808591
[TBL] [Abstract][Full Text] [Related]
11. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
[TBL] [Abstract][Full Text] [Related]
12. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.
Daubert JP; Zareba W; Cannom DS; McNitt S; Rosero SZ; Wang P; Schuger C; Steinberg JS; Higgins SL; Wilber DJ; Klein H; Andrews ML; Hall WJ; Moss AJ;
J Am Coll Cardiol; 2008 Apr; 51(14):1357-65. PubMed ID: 18387436
[TBL] [Abstract][Full Text] [Related]
13. Effect of left ventricular assist device placement on preexisting implantable cardioverter-defibrillator leads.
Ambardekar AV; Lowery CM; Allen LA; Cannon AP; Cleveland JC; Lindenfeld J; Brieke A; Sauer WH
J Card Fail; 2010 Apr; 16(4):327-31. PubMed ID: 20350700
[TBL] [Abstract][Full Text] [Related]
14. Ventricular proarrhythmic effects of atrial fibrillation are modulated by depolarization and repolarization anomalies in patients with left ventricular dysfunction.
Lemola K; Khan R; Nattel S; Talajic M; Roy D; Guerra PG; Lemola S; Dubuc M; Thibault B; Macle L; Khairy P
Pacing Clin Electrophysiol; 2009 Jan; 32(1):99-105. PubMed ID: 19140919
[TBL] [Abstract][Full Text] [Related]
15. Atrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients.
Smit MD; Van Dessel PF; Rienstra M; Nieuwland W; Wiesfeld AC; Tan ES; Anthonio RL; Van Veldhuisen DJ; Van Gelder IC
Europace; 2006 Aug; 8(8):566-72. PubMed ID: 16864611
[TBL] [Abstract][Full Text] [Related]
16. Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial.
Barsheshet A; Goldenberg I; Moss AJ; Huang DT; Zareba W; McNitt S; Klein HU; Guetta V
J Cardiovasc Electrophysiol; 2011 Nov; 22(11):1237-42. PubMed ID: 21615813
[TBL] [Abstract][Full Text] [Related]
17. Implantable cardioverter defibrillator therapy in adults with congenital heart disease: who is at risk of shocks?
Koyak Z; de Groot JR; Van Gelder IC; Bouma BJ; van Dessel PF; Budts W; van Erven L; van Dijk AP; Wilde AA; Pieper PG; Sieswerda GT; Mulder BJ
Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):101-10. PubMed ID: 22095638
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure.
Desai H; Aronow WS; Ahn C; Gandhi K; Hussain S; Lai HM; Sharma M; Frishman WH; Cohen M; Sorbera C
Am J Cardiol; 2010 May; 105(9):1336-8. PubMed ID: 20403488
[TBL] [Abstract][Full Text] [Related]
19. Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register.
Weeke P; Johansen JB; Jørgensen OD; Nielsen JC; Møller M; Videbæk R; Højgaard MV; Riahi S; Jacobsen PK
Europace; 2013 Aug; 15(8):1150-7. PubMed ID: 23407630
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of the adrenergic system and implantable cardioverter-defibrillator therapies in patients with heart failure.
Chemello D; Rohde LE; Santos KG; Silvello D; Goldraich L; Pimentel M; Rosa PR; Zimerman L; Clausell N
Europace; 2010 May; 12(5):686-91. PubMed ID: 20185488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
